Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.

Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interdependent pharmacokinetic (PK) and pharmacodynamics (PD) properties. Understanding the PK and PD of mAbs and their biological and mechanistic underpinnings are crucial in enabling their design and selection, designing appropriate efficacy and toxicity studies, translating PK/PD parameters to humans, and optimizing dose and regimen to maximize success in the clinic. Significant progress has been made in this field however many critical questions still remain. This article gives a brief overview of the PK and PD of mAbs, factors that influence them, and areas of ongoing inquiry. Current tools and translational approaches to predict the PK/PD of mAbs in humans are also discussed.

[1]  William J Jusko,et al.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.

[2]  T. Prueksaritanont,et al.  Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited , 2010, Biopharmaceutics & drug disposition.

[3]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[4]  J. Reichert Antibodies to watch in 2016 , 2016, mAbs.

[5]  Irene van den Broek,et al.  Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  Meindert Danhof,et al.  Systems pharmacology - Towards the modeling of network interactions. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  R. Kelley,et al.  Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys , 2013, mAbs.

[8]  D. Salinger,et al.  Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies , 2011, Clinical pharmacokinetics.

[9]  B. Ploeger,et al.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. , 2008, Trends in pharmacological sciences.

[10]  M. Sliwkowski,et al.  Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose , 2012, Cancer Chemotherapy and Pharmacology.

[11]  Denise M O'Hara,et al.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies , 2016, mAbs.

[12]  Rene Bruno,et al.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[13]  G Levy,et al.  Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.

[14]  F. Theil,et al.  Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.

[15]  N. Benson,et al.  The rise of systems pharmacology in drug discovery and development. , 2014, Future medicinal chemistry.

[16]  F. Theil,et al.  Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations , 2012, The AAPS Journal.

[17]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[19]  D. Shah,et al.  Antibody biodistribution coefficients , 2013, mAbs.

[20]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[21]  Zinnia P. Parra-Guillen,et al.  Review on modeling anti-antibody responses to monoclonal antibodies , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  Saileta Prabhu,et al.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.

[23]  Min Xu,et al.  Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A , 2016, mAbs.

[24]  L. V. D. van de Putte,et al.  A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[25]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[26]  Kiran Mukhyala,et al.  Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.

[27]  Y. Yabe,et al.  Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. , 2011, Drug metabolism and pharmacokinetics.

[28]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[29]  M. P. Griffin,et al.  A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.

[30]  F. Theil,et al.  Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans , 2012, Pharmaceutical Research.

[31]  S. Iyer,et al.  Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  J. Treadway,et al.  The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[33]  Ken A. Dill,et al.  In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability , 2014, Proceedings of the National Academy of Sciences.

[34]  G. Proetzel,et al.  Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. , 2014, Methods.

[35]  Y. Vugmeyster,et al.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.

[36]  I. Sandlie,et al.  Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding* , 2009, The Journal of Biological Chemistry.

[37]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[38]  S. Tannenbaum,et al.  Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. , 2009, British journal of clinical pharmacology.

[39]  F. Brennan,et al.  Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases , 2014, Drug development research.

[40]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[41]  John D. Davis,et al.  Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. , 2016, Biopharmaceutics & drug disposition.

[42]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[43]  Honghui Zhou,et al.  Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look , 2009, Journal of clinical pharmacology.

[44]  Jeanine L. Bussiere,et al.  Species selection considerations for preclinical toxicology studies for biotherapeutics , 2008 .

[45]  P. Vicini,et al.  A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.

[46]  S. Prabhu,et al.  Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies , 2012, mAbs.

[47]  M. Morris,et al.  Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration , 2012, The AAPS Journal.

[48]  Sean P. Lear,et al.  Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody , 2012, Toxicologic pathology.

[49]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[50]  H. Kropshofer,et al.  Immunogenicity: Its Impact on ADME of Therapeutic Biologics , 2015 .

[51]  Michael M. Schmidt,et al.  Factors determining antibody distribution in tumors. , 2008, Trends in pharmacological sciences.

[52]  M. Dennis,et al.  Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 , 2011, mAbs.

[53]  E. Kraynov,et al.  A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition , 2012, Journal of Pharmacology and Experimental Therapeutics.

[54]  K Dane Wittrup,et al.  Practical theoretic guidance for the design of tumor-targeting agents. , 2012, Methods in enzymology.

[55]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[56]  W. Jusko,et al.  Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies , 2015 .

[57]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[58]  Saileta Prabhu,et al.  Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? , 2012, Expert opinion on drug metabolism & toxicology.

[59]  Y. Vugmeyster,et al.  Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species , 2011, Pharmaceutical Research.

[60]  Lisa J. Bernstein,et al.  A strategy for risk mitigation of antibodies with fast clearance , 2012, mAbs.

[61]  K. Gadkar,et al.  Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  J. Balthasar,et al.  Mechanistic considerations for the use of monoclonal antibodies for cancer therapy , 2014, Cancer biology & medicine.

[63]  Y. Vugmeyster,et al.  Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics , 2012, The AAPS Journal.